Zai Lab reports 81.8% response rate in lung cancer trial
Zai Lab (NASDAQ:ZLAB) reported an 81.8% confirmed tumor response rate in a Phase 1b trial of zocilurtatug pelitecan plus atezolizumab for first-line treatment of extensive-stage small cell lung cancer.










